Related Experiment Videos
Plasma tetranectin and colorectal cancer
C K Høgdall1, M Christiansen, B Nørgaard-Pedersen
1Dept. of Clinical Biochemistry, Statens Seruminstitut, Copenhagen, Denmark.
European Journal of Cancer (Oxford, England : 1990)
|June 1, 1995
Summary
Plasma tetranectin (PL-TN) shows prognostic significance in colorectal cancer, particularly in Dukes
Area of Science:
- Oncology
- Biomarker Research
- Colorectal Cancer
Background:
- Colorectal cancer (CRC) prognosis remains challenging, necessitating novel prognostic markers.
- Plasma tetranectin (PL-TN) is a potential biomarker, but its prognostic value in CRC requires further investigation.
Purpose of the Study:
- To retrospectively evaluate the prognostic significance of plasma tetranectin (PL-TN) in a cohort of colorectal cancer patients.
Main Methods:
- Retrospective analysis of 504 colorectal cancer patients across Dukes' stages A to D.
- Cox multivariate analysis and lifetable methods were employed to assess prognostic variables.
- Follow-up duration ranged from 7 to 12 years.
Main Results:
- Plasma tetranectin (PL-TN) was a significant prognostic variable in Dukes' B (second strongest, RH=3.3) and Dukes' D (only variable, RH=1.7) stages.
- Dukes' staging was the strongest prognostic variable overall, with PL-TN as the second strongest.
- Low PL-TN levels correlated with shortened survival, as illustrated by lifetables.
Conclusions:
- Plasma tetranectin (PL-TN) is a valuable prognostic marker in colorectal cancer, particularly in advanced stages (Dukes' B and D).
- PL-TN, alongside clinical staging, can aid in refining prognostic assessments for colorectal cancer patients.
- Further research into the biological mechanisms underlying PL-TN's prognostic role is warranted.